2020-06082. Blood Products Advisory Committee; Postponed  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The meeting of the Blood Products Advisory Committee (BPAC) scheduled for April 2-3, 2020, is postponed. The Food and Drug Administration (FDA), like other government agencies, is taking the necessary steps to ensure the Agency is prepared to continue our vital public health mission in the event that our day-to-day operations are impacted by the Start Printed Page 16369COVID-19 public health emergency. Therefore, we are canceling or postponing all non-essential meetings through the month of April. We will reassess on an ongoing basis for future months. Therefore, this meeting is being postponed. The meeting was announced in the Federal Register on February 13, 2020.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Christina Vert, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6268, Silver Spring, MD 20993-0002, 240-402-8054, christina.vert@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting, which was announced in the Federal Register of February 13, 2020, 85 FR 8299.

    Start Signature

    Dated: March 18, 2020.

    Lowell J. Schiller,

    Principal Associate Commissioner for Policy.

    End Signature End Further Info End Preamble

    [FR Doc. 2020-06082 Filed 3-20-20; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
03/23/2020
Department:
Health and Human Services Department
Agency:
Food and Drug Administration
EntryType:
Notice
Action:
Notice.
Document Number:
2020-06082
Pages:
16368-16369 (2 pages)
Docket Numbers:
Docket No. FDA-2020-N-0008
SectionNoes:
PDF File:
2020-06082.pdf